Evidence of occupational exposure risks to novel anticancer agents is limited and yet to be formally evaluated from the Australian healthcare perspective.
Methods
From March to September 2013 medical databases, organizational policies, drug monographs, and the World Wide Web were searched for evidence relating to occupational exposure to monoclonal antibodies, fusion proteins, gene therapies, and other unclassified novel anticancer agents.
Results
Australian legislation, national and international guidelines, and drug company information excluded novel agents or provided inconsistent risk assessments and safe handling recommendations. Monoclonal antibody guidelines reported conflicting information and were often divergent with available evidence and pharmacologic rationale demonstrating minimal internalisation ability and occupational exposure risk. Despite similar physiochemical, pharmacologic, and internalisation properties to monoclonal antibodies, fusion proteins were included in only a minority of guidelines. Clinical directives for the safe handling of gene therapies and live vaccines were limited, where available focusing on prevention against exposure and cross-contamination. Although mechanistically different, novel small molecule agents (proteasome inhibitors), possess similar physiochemical and internalisation properties to traditional cytotoxic agents warranting cytotoxic classification and handling.
Conclusion
Novel agents are rapidly emerging into clinical practice, and healthcare personnel have few resources to evaluate risk and provide safety recommendations. Novel agents possess differing physical, molecular and pharmacological profiles compared to traditional cytotoxic anticancer agents. Evaluation of occupational exposure risk should consider both toxicity and internalisation. Evidence-based guidance able to direct safe handling practices for novel anticancer agents across a variety of clinical settings is urgently required.
National Institute for Occupational Safety and Health (NIOSH). List of antineoplastic and other hazardous drugs in health care settings. Ohio: Author, 2012.
2.
National Occupational Health and Safety Commission (NOHSC). Approved criteria for classifying hazardous substances [NOHSC:1008(2004)]. Australian National Standard. 3rd revision. Canberra: Author, 2004.
3.
Commission Directive 2001/59/EC of 6 August 2001 adapting to technical progress for the 28th time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Off J Eur Commun, No. L225 (21 August 2001).
4.
EC Council Directive 67/548/EEC on the approximation of the laws RAAPRTTC, packaging and labelling of dangerous substances. Off J Eur Commun, No. L196 (16 August 1967).
5.
AdamsJKauffmanM. Development of the proteasome inhibitor Velcade™ (Bortezomib). Canc Investig2004; 22: 304–311.
6.
Australian Register of Therapeutic Goods (ARTG). Therapeutic goods administration (TGA), www.ebs.tga.gov.au/ (accessed 30 September 2013).
Bacillus Calmette and Guerin (Oncotice) TGA product information. Merck Sharp & Dohme. Revision date: 1 September 2012.
13.
GinnSLAlexanderIEEdelsteinML. Gene therapy clinical trials worldwide to 2012 – an update. J Gene Med2013; 15: 65–77.
14.
BamfordKBWoodSShawRJ. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS teaching hospital trust. QJM2005; 98: 75–86.
15.
Gene Technology Act 2000. Act No. 169/2000 as amended. Compilation prepared on 24 January 2012 taking into account amendments up to Act No. 58 of 2011.
16.
SHPA. Guidelines for medicines prepared in Australian hospital pharmacy departments. J Pharm Pract Res2010; 40: 133–143.
17.
ConnorTMcLauchlanRVandenbrouckeJ. ISOPP standards of practice – cytotoxics. J Oncol Pharm Pract2007; 13: 13–81.
18.
The scientific advisory committee on genetic modification (SACGM) compendium of guidance. Part 6: guidance on the use of genetically modified microorganisms in a clinical setting. Health and Safety Executive (HSE), First published January 2007.
19.
LiossisS-NCTsokosGC. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol2005; 116: 721–729.
20.
Guideline for the preparation or manipulation of monoclonal antibodies (MABs) and related compounds such as fusion proteins, used in the treatment of cancer. Version 2.0. Pan Birmingham cancer network, 2012.
21.
Clinical oncology society of Australia. Cancer pharmacists group position statement. Safe handling of monoclonal antibodies in healthcare settings, Melbourne: Clinical Oncology Society of Australia, 2013.
22.
Etanercept (Enbrel) Material Safety Data Sheet (MSDS). Amgen. Revision number 3. Issue date 12 February 2013.
23.
Abatacept Material Safety Data Sheet (MSDS). Bristol-Myers Squibb. Version 1.6. Issue date 4 June 2007.
24.
AndradyCChesterKASharmaSK. Antibody-enzyme fusion proteins for cancer therapy. Immunotherapy2011; 3: 193–211.
25.
MascelliMAZhouHSweetR. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J Clin Pharmacol2007; 47: 553–565.
26.
MellorJDBrownMPIrvingHR. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol2013; 6: 1–10.
27.
Guidance for industry S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals (ICH S6). International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH), 1997.
28.
MaibachHConantM. Contact urticaria to a corticosteroid cream: polysorbate 60. Contact Dermatitis2006; 3: 350–351.
29.
KerwinBA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharmaceut Sci2008; 97: 2924–2935.
30.
OverdijkMBVerploegenSvan den BrakelJH. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol (Baltimore, Md : 1950)2011; 187: 3383–3390.
31.
UedaNTsukamotoHMitomaH. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α. Inflamm Bowel Dis2013; 19: 1224–1231.
32.
Monoclonal antibodies risk management for Northern Sydney Local Health District (NSLHD). Document No. PR2013_001. Department of Oncology, Division of Medicine, Northern Sydney Local Health District Hospitals, 2013.
33.
HalsenGKramerI. Assessing the risk to health care staff from long-term exposure to anticancer drugs – the case of monoclonal antibodies. J Oncol Pharm Pract2011; 17: 68–80.
34.
LangfordSFradgleySEvansM. Assessing the risk of handling monoclonal antibodies. Hospital Pharmacist2008; 15: 60–64.
35.
ConnorTHMacKenzieBAShould monoclonal antibodies and their conjugates be considered occupational hazards. In: KurtEGoodmanN (eds). Safety Considerations in Oncology Pharmacy Fall, Ohio: National Institute for Occupational Safety and Health, 2011, pp. 13–16.
KaestliLFonzo-ChristeCBonfillonC. Development of a standardised method to recommend protective measures to handle hazardous drugs in hospitals. Eur J Hosp Pharm2013; 20: 100–105.
41.
LightwoodDO'DowdVCarringtonB. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol2013; 425: 577–593.
42.
MailletACongy-JolivetNLe GuellecS. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharmaceut Res2008; 25: 1318–1326.
SaltzmanWMSherwoodJKAdamsDR. Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol Bioeng2000; 67: 253–264.
45.
SamsonGGarcia de la CaleraADupuis-GirodS. Ex vivo study of bevacizumab transport through porcine nasal mucosa. Eur J Pharm Biopharm2012; 80: 465–469.
46.
Falero-DiazGChallacombeSRahmanD. Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery. Int Arch Allergy Immunol2000; 122: 143–150.
47.
PleyerUMilaniJKDukesA. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Investig Ophthalmol Vis Sci1995; 36: 52–61.
48.
OchiHAbrahamMIshikawaH. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25− LAP+ T cells. Nat Med2006; 12: 627–635.
49.
PetschowBWTalbottRD. Reduction in virus-neutralizing activity of a bovine colostrum immunoglobulin concentrate by gastric acid and digestive enzymes. J Pediatr Gastroenterol Nutr1994; 19: 228–235.
50.
TacketCOLosonskyGLinkH. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med1988; 318: 1240–1243.
51.
VermeerAWNordeW. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J2000; 78: 394–404.
52.
ChuWHonC-YDanylukQ. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. J Oncol Pharm Pract2012; 18: 46–51.
53.
FransmanWVermeulenRKromhoutH. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Ann Occup Hyg2004; 48: 237–244.
54.
GandreBKramerI. Cytotoxic surface contamination in a robotic system compared with manual preparation. Eur J Hosp Pharm2012; 19: 151–151.
55.
HonC-YTeschkeKChuW. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. J Occup Environ Hyg2013; 10: 374–383.
56.
KiffmeyerTKKubeCOpiolkaS. Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety. Pharmaceut J2002; 268: 33–33.
57.
SiderovJKirsaSRM. Surface contamination of cytotoxic chemotherapy preparation areas in Australian hospital pharmacy departments. J Pharm Pract Res2009; 39: 117–121.
58.
Australian and New Zealand Standard. AS/NZS 1716:2012. Respiratory protective devices. 7th ed. New Zealand: Standards Australia Limited/Standards New Zealand, Melbourne.
59.
Australian and New Zealand Standard. AS/NZS 1715:2009. Selection, use and maintenance of respiratory protective equipment. New Zealand: Standards Australia Limited/Standards.
60.
AllwoodMStanleyAWrightP. The cytotoxics handbook, 4th ed. Abingdon, UK: Radcliffe Medical Press, 2002.
61.
HarrisonBKloosM. Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs. J Oncol Pharm Pract1999; 5: 61–66.
62.
JorgensonJSpiveySCanannD. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm2008; 43: 723–727.
63.
HarrisonBPetersBBingM. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health-Syst Pharm2006; 63: 1736–1744.
64.
McMichaelDJeffersonDCareyE. Utility of the PhaSeal closed system drug transfer device. Am J Pharm Benefits2011; 3: 9–16.
65.
SessinkPRolfMRydenN. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm1999; 34: 1311–1317.
66.
SiderovJKirsaSMcLauchlanR. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. J Oncol Pharm Pract2010; 16: 19–25.
67.
SpiveySConnorT. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV preparation with a closed system. Hosp Pharm2003; 38: 135–139.
68.
BironADLavoie-TremblayMLoiselleCG. Characteristics of work interruptions during medication administration. J Nurs Scholarsh2009; 41: 330–336.
69.
Raban MZ and Westbrook JI. Are interventions to reduce interruptions and errors during medication administration effective? A systematic review. BMJ Qual Saf 2013. DOI:10.1136/bmjqs-2013-002118.
70.
KieseSPapppenbergerAFriessW. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharmaceut Sci2008; 97: 4347–4366.
71.
SreedharaAGloverZKPirosN. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharmaceut Sci2012; 101: 21–30.
AustinPEliaM. Improved aseptic technique can reduce variable contamination rates of ward-prepared parenteral doses. J Hosp Infect2013; 83: 160–163.
74.
ThomasMSanbornMCouldryR. I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom. Am J Health Syst Pharm2005; 62: 2386–2392.
75.
TrisselLGentempoJAndersonR. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding. Am J Health Syst Pharm2005; 62: 285–288.
76.
MattnerFGastmeierP. Bacterial contamination of multiple-dose vials: a prevalence study. Am J Infect Contr2004; 32: 12–16.
Bortezomib (Velcade) product information. Jannsen. Revision date: 20 November 2012.
79.
Denosumab (Xgeva) product information. Amgen. Revision date: 5 March 2013.
80.
ShpilbergOJackischC. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Canc2013; 109: 1556–1561.
81.
Cisplatin (cas 15663-27-1) material safety data sheet (MSDS). GuideChem.
82.
National Institute for Occupational Safety and Health (NIOSH). List of antineoplastic and other hazardous drugs in healthcare settings: proposed additions and deletions to the NIOSH hazardous drug list-charge to reviewers. Ohio: Author, 2012.
83.
Brentuximab-Vedotin (Adcetris) FDA product information. SeattleGenetics. Revision date: January 2012.
84.
Trastuzumab-Emtansine (Kadcyla) FDA product information. Genentech. Revision date: May 2013.
85.
Aflibercept (Eylea) material safety data sheet (MSDS). Bayer Australia Ltd. Version 1.0. Revision date: 22 September 2011.
86.
Aflibercept (Eylea) product information. Bayer Australia Ltd. Revision date: 5 April 2013.
87.
Alemtuzumab (Campath) material safety data sheet (MSDS). Berlex Biosciences. Revision date: 4 June 2002.
88.
Alemtuzumab (Campath) FDA product information. Genzyme Corporation. Revision date: 19 September 2007.
